BMI View: SSA's pharmaceutical market will remain challenging for multinational drugmakers as thecombination of industry- and country-level risks show limited signs of abating. This will ensure thatdrugmakers take a targeted approach to key markets in the region, where the rewards are brighter forinnovative drugmakers' portfolios and have longer-term potential.
Headline Expenditure Projections
Pharmaceuticals: USD12.0bn in 2016 to USD12.3bn in 2017; 3.1% in US dollar terms.
Healthcare: USD79.1bn in 2016 to USD80.2bn in 2017; 1.4% in US dollar terms.
The Sub-Saharan Africa (SSA) average in our Innovative Pharmaceuticals Risk/Reward Index (RRI)significantly underperforms the global average. The indicators used to assess the attractiveness of apharmaceutical market are now visible, improving the transparency of the index system and enabling theidentification of regional or group outperformers across single indicators. A market's RRI score is made upof a sum of the Rewards score (Industry Rewards + Country Rewards) and the Risks score (Industry Risks +Country Risks).